An 'amazing' family has faced a shocking double health crisis as both a mother and her 12-year-old daughter were diagnosed ...

DelveInsight’s Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Head and neck cancers — including oral, throat, voice box (larynx), nasal cavity, sinuses, salivary glands, and thyroid cancers — represent a diverse group of diseases that are significantly ...

A reduced dose of elective radiation is safe and does not compromise treatment efficacy in patients with head and neck ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC).

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...